Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06451497 |
| This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 100 |
| Zumutor Biologics Inc.INDUSTRY |
| 1 |
| Apr 2, 2026 |
| clinicaltrials |
| NCT06222593 | Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC | recruiting | Phase 1 / Phase 2 | 28 | State University of New York at BuffaloOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | recruiting | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06336902 | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06908928 | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | recruiting | Phase 1 | 52 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04808323 | MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | recruiting | Phase 1 | 22 | Medical College of WisconsinOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06211335 | Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 24 | University of California, DavisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07456878 | Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | recruiting | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05901545 | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer | recruiting | Phase 1 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05526924 | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07444281 | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer | recruiting | Phase 1 | 24 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | recruiting | Phase 1 | 80 | ProteinQure Inc.INDUSTRY | 2 | Feb 23, 2026 | clinicaltrials |
| NCT05488522 | SBRT With Atezo/Bev for HCC | recruiting | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | recruiting | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials